GlaxoSmithKline has begun a COVID-19 clinical trial with China’s Clover Biopharmaceuticals, combining its booster with the biotech’s early-stage vaccine.
Almost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – and now the UK pharma is reportedly planning its own mega-merger with Gilead. <
Gilead has begun testing its COVID-19 coronavirus antiviral remdesivir in the UK, announcing plans to trial the drug in patients in England and Scotland.
South Korea’s Celltrion has joined the many pharma companies fighting the COVID-19 coronavirus outbreak, saying it is working on an antibody-based antiviral and a self-testing diagnosis kit
Gilead has said it has stopped accepting “compassionate use” requests for its potential coronavirus antiviral remdesivir because it cannot keep pace with demand as health systems become ove